118TH CONGRESS 
1ST SESSION H. R. 2365 
AN ACT 
To direct the Secretary of Health and Human Services to 
carry out a national project to prevent, diagnose, treat, 
and cure Parkinson’s, to be known as the National Par-
kinson’s Project, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Dr. Emmanuel Bili-
rakis and Honorable Jennifer Wexton National Plan to 
End Parkinson’s Act’’. 
SEC. 2. NATIONAL PARKINSON’S PROJECT. 
Title III of the Public Health Service Act (42 U.S.C. 
241 et seq.) is amended by adding at the end: 
‘‘PART W—PARKINSON’S AND RELATED 
DISORDERS 
‘‘SEC. 399OO. NATIONAL PARKINSON’S PROJECT. 
‘‘(a) DEFINITION OF PARKINSON’S.—In this section, 
the term ‘Parkinson’s’ means— 
‘‘(1) Parkinson’s disease; and 
‘‘(2) all other neurodegenerative Parkinsonisms, 
including multiple system atrophy, corticobasal de-
generation, progressive supranuclear palsy, and Par-
kinson’s-related dementia. 
‘‘(b) ESTABLISHMENT.—The Secretary shall carry 
out a national project, to be known as the National Par-
kinson’s Project (referred to in this section as the 
‘Project’), to prevent, diagnose, treat, and cure Parkin-
son’s. 
‘‘(c) 
ACTIVITIES
CARRIED
OUT
THROUGH 
PROJECT.—In carrying out the Project, the Secretary 
shall—
‘‘(1) create, maintain, and periodically update 
an integrated national plan to prevent, diagnose, 
treat, and cure Parkinson’s, ameliorate symptoms, 
and slow or stop progression; 
‘‘(2) carry out the annual assessment under 
subsection (d); 
‘‘(3) provide information, including— 
‘‘(A) an estimate of the level of current 
Federal investment in preventing, diagnosing, 
treating, and curing Parkinson’s, ameliorating 
symptoms, and slowing or stopping progression; 
and 
‘‘(B) if applicable, an estimate of the in-
vestment necessary to prevent, diagnose, treat, 
and cure Parkinson’s, ameliorate symptoms, 
and slow or stop progression; 
‘‘(4) coordinate research and services across all 
Federal agencies related to Parkinson’s; 
‘‘(5) encourage the development of safe and ef-
fective treatments, strategies, and other approaches 
to prevent, diagnose, treat, and cure Parkinson’s, 
ameliorate symptoms, and slow or stop progression; 
‘‘(6) improve the— 
‘‘(A) early diagnosis of Parkinson’s; and
‘‘(B) coordination of the care and treat-
ment of individuals with Parkinson’s; 
‘‘(7) review the impact of Parkinson’s on the 
physical, mental, and social health of individuals liv-
ing with Parkinson’s and their caregivers and fami-
lies; 
‘‘(8) coordinate with international bodies, to the 
extent possible, to integrate and inform the mission 
to prevent, diagnose, treat, and cure Parkinson’s, 
ameliorate symptoms, and slow or stop progression 
globally; and 
‘‘(9) to the extent practicable, collaborate with 
other entities to prevent duplication of existing re-
search activities for related disorders. 
‘‘(d) ANNUAL ASSESSMENT.—Not later than 24 
months after the date of enactment of this section, and 
annually thereafter, the Secretary shall carry out an as-
sessment of the Nation’s progress in preparing for, and 
responding to, the escalating burden of Parkinson’s, in-
cluding— 
‘‘(1) recommendations for priority actions based 
on the assessment; 
‘‘(2) a description of any steps that are planned 
or have already been taken to implement such rec-
ommendations, including whether such recommenda-
tions can be implemented under existing law; and 
‘‘(3) such other items as the Secretary deter-
mines appropriate. 
‘‘(e) ADVISORY COUNCIL.— 
‘‘(1) IN GENERAL.—The Secretary shall estab-
lish and maintain an Advisory Council on Parkin-
son’s Research, Care, and Services (referred to in 
this section as the ‘Advisory Council’) to advise the 
Secretary on Parkinson’s-related issues. 
‘‘(2) MEMBERSHIP.— 
‘‘(A) FEDERAL MEMBERS.—The Advisory 
Council shall be comprised of experts, to be ap-
pointed by the Secretary, who collectively are 
from various backgrounds and perspectives, in-
cluding at least one member from each of— 
‘‘(i) the Centers for Disease Control 
and Prevention; 
‘‘(ii) the Administration on Commu-
nity Living; 
‘‘(iii) the Centers for Medicare & Med-
icaid Services; 
‘‘(iv) 
the 
National 
Institutes 
of 
Health;
‘‘(v) the Agency for Healthcare Re-
search and Quality; 
‘‘(vi) the Department of Veterans Af-
fairs; 
‘‘(vii) the Food and Drug Administra-
tion; 
‘‘(viii) the National Science Founda-
tion; 
‘‘(ix) the Department of Defense; 
‘‘(x) the Environmental Protection 
Agency; 
‘‘(xi) the Office of Minority Health; 
‘‘(xii) the Indian Health Service; 
‘‘(xiii) the Office of the Surgeon Gen-
eral of the Public Health Service; and 
‘‘(xiv) other relevant Federal depart-
ments and agencies as determined by the 
Secretary. 
‘‘(B) NON-FEDERAL MEMBERS.—In addi-
tion to the members listed in subparagraph (A), 
the Advisory Council shall include 10 expert 
members, to be appointed by the Secretary, who 
shall include representatives of minority com-
munities, communities disproportionately af-
fected by Parkinson’s, and communities under-
represented in Parkinson’s research, who shall 
each be from outside the Federal Government, 
and who shall include— 
‘‘(i) 2 Parkinson’s patient advocates, 
at least 1 of whom is living with young- 
onset Parkinson’s; 
‘‘(ii) 1 Parkinson’s family caregiver; 
‘‘(iii) 1 health care provider; 
‘‘(iv) 2 biomedical researchers with 
Parkinson’s-related 
expertise 
in 
basic, 
translational, clinical, or drug development 
science; 
‘‘(v) 1 movement disorder specialist 
who treats Parkinson’s patients; 
‘‘(vi) 1 dementia specialist who treats 
Parkinson’s patients; and 
‘‘(vii) 2 representatives from nonprofit 
organizations that have demonstrated ex-
perience in Parkinson’s-related research or 
Parkinson’s-related patient care and other 
services. 
‘‘(C) REPRESENTATION.—The Secretary 
shall ensure that the members of the Advisory 
Council are collectively representative of agen-
cies, professions, individuals, and entities con-
cerned with, or affected by, activities under this 
section. 
‘‘(3) MEETINGS.— 
‘‘(A) FREQUENCY.—The Advisory Council 
shall meet— 
‘‘(i) at least once each quarter during 
the 2-year period beginning on the date on 
which the Advisory Council is established; 
and 
‘‘(ii) at the Secretary’s discretion 
after such period. 
‘‘(B) ANNUAL RESEARCH MEETING.—Not 
later than 24 months after the date of enact-
ment of this section, and every year thereafter, 
the Advisory Council shall convene a meeting of 
Federal and non-Federal organizations to dis-
cuss Parkinson’s research. 
‘‘(C) OPEN
MEETINGS.—The meetings 
under subparagraphs (A) and (B) shall be open 
to the public. 
‘‘(4) ANNUAL
REPORT.—Not later than 18 
months after the date of enactment of this section, 
and every year thereafter, the Advisory Council shall 
provide to the Secretary and Congress a report con-
taining—
‘‘(A) a list of all federally-funded efforts in 
Parkinson’s research, prevention, diagnosis, 
treatment, clinical care, and institutional-, 
home-, and community-based programs and the 
outcomes of such efforts; 
‘‘(B) recommendations for priority actions 
to 
expand, 
eliminate, 
coordinate, 
refocus, 
streamline, or condense Federal programs based 
on each program’s performance, mission, scope, 
and purpose; 
‘‘(C) recommendations to— 
‘‘(i) reduce the financial impact of 
Parkinson’s on families living with Parkin-
son’s; 
‘‘(ii) improve health outcomes for, and 
the quality of life of, individuals living with 
Parkinson’s; 
‘‘(iii) prevent Parkinson’s, ameliorate 
symptoms, and slow or stop progression; 
‘‘(iv) improve the quality of care pro-
vided to beneficiaries with Parkinson’s who 
receive coverage through a federally-funded 
health care program, such as the Medicare 
program under title XVIII of the Social
Security Act or the Medicaid program 
under title XIX of such Act; 
‘‘(v) research the association between 
environmental triggers and Parkinson’s to 
help reduce exposure to potential triggers; 
and 
‘‘(vi) research and better understand 
the underlying factors contributing to Par-
kinson’s; 
‘‘(D) priority actions to improve all feder-
ally-funded efforts in Parkinson’s research, pre-
vention, diagnosis, treatment, clinical care, and 
institutional-, home-, and community-based pro-
grams; 
‘‘(E) an evaluation of the implementation, 
including outcomes, of the national plan under 
subsection (c)(1); and 
‘‘(F) implementation steps to address the 
recommendations and priority actions under 
subparagraphs (B), (C), and (D), based in part 
on the evaluation under subparagraph (E). 
‘‘(5) TERMINATION.—The Advisory Council 
shall terminate at the end of calendar year 2035. 
‘‘(f) INFORMATION SHARING.—Each Federal depart-
ment and agency that has information relating to Parkin-
son’s shall share such information with the Secretary con-
sistent with the statutory obligations of such department 
or agency regarding disclosure of information, as nec-
essary to enable the Secretary to complete a report under 
subsection (e)(4). 
‘‘(g) SUNSET.—The section shall cease to be effective 
at the end of calendar year 2035.’’. 
Passed the House of Representatives December 14, 
2023. 
Attest: 
Clerk.
118TH CONGRESS 
1ST SESSION 
H. R. 2365 
AN ACT 
To direct the Secretary of Health and Human 
Services to carry out a national project to pre-
vent, diagnose, treat, and cure Parkinson’s, to be 
known as the National Parkinson’s Project, and 
for other purposes.